Norcantharidin overcomes vemurafenib resistance in melanoma by inhibiting pentose phosphate pathway and lipogenesis via downregulating the mTOR pathway

Norcantharidin overcomes vemurafenib resistance in melanoma by inhibiting pentose phosphate pathway and lipogenesis via downregulating the mTOR pathway

Melanoma is the most aggressive type of skin cancer with a high incidence and low survival rate. More than half of melanomas present the activating BRAF mutations, along which V600E mutant represents 70%–90%. Vemurafenib (Vem) is an FDA-approved small-molecule kinase inhibitor that selectively targe...

Full description

Bibliographic Details
Main Authors: Lei Wang, Wuxiyar Otkur, Aman Wang, Wen Wang, Yitong Lyu, Lei Fang, Xiu Shan, Mingzhou Song, Yan Feng, Yi Zhao, Hai-Long Piao, Huan Qi, Ji-Wei Liu
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Pharmacology
Subjects:
vemurafenib
resistance
norcantharidin
pentose phosphate pathway
lipogenesis
mTOR. Norcantharidin overcomes Vem-resistance in melanoma
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.906043/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.906043/full

Similar Items